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We developed a method for immunoaffinity purification of Saccharomyces cerevisiae adenylyl cyclase based on creating a fusion with a small peptide epitope. Using oligonucleotide technology to encode the peptide epitope we constructed a plasmid that expressed the fusion protein from the S. cerevisiae alcohol dehydrogenase promoter ADHI. A monoclonal antibody previously raised against the peptide was used to purify adenylyl cyclase by affinity chromatography. The purified enzyme appeared to be a multisubunit complex consisting of the 200-kilodalton adenylyl cyclase fusion protein and an unidentified 70-kilodalton protein. The purified protein could be activated by RAS proteins. Activation had an absolute requirement for a guanine nucleoside triphosphate.
We have been studying the two RAS genes, RASI and RAS2, of Saccsharony(ces cereivisiae as models for the mammalian ras oncogenes. The yeast RAS proteins are structurally, functionally, and biochemically similar to their mammalian counterparts and at least one of their effector systems is known (3, 7, 8, 18, 24, 34, 36, 38) . The yeast RAS genes were originally isolated by using mammalian ras genes to screen libraries from S. cerev,isiae (7, 24) . They encode proteins that are highly homologous to the mammalian ras proteins, particularly in their amino-terminal half. Both yeast and mammalian RAS proteins undergo similar processing events and localize to membrane fractions (6, 11, 25, 30, 42) . All RAS proteins bind guanine nucleotides and possess an intrinsic GTPase activity. The GTPase activity is reduced in a number of oncogenic forms of mammalian ras proteins containing point mutations (12, 21, 29, 33, 34) . Analogous mutations in the yeast RAS proteins also result in substantially reduced GTPase activity (36) . The enzymatic properties of RAS proteins have led to their inclusion in the class of signal-transducing proteins that bind guanine nucleotides and activate a variety of effector systems. It is generally assumed that these proteins are turned off by GTP hydrolysis (reviewed in reference 13) .
We have previously demonstrated that RAS proteins are potent activators of yeast adenylyl cyclase (3, 38) . In our previous studies, we carried out in vitro measurements of adenylyl cyclase activity in crude yeast membrane extracts supplemented with purified RAS proteins bound to various guanine nucleotides. Under these conditions, RAS2 protein activated adenylyl cyclase when bound to GTP and GTP analogs, but not when bound to the stable GDP analog GDP-,BS [guanosine-5'0-(2-thiodiphosphate)]. RAS2 protein bound to GDP itself gave intermediate levels of activation, presumably because GTP was being generated during the assay from GDP by factors present in the crude membrane extract (3, 9, 10) . These studies, while consistent with the G-protein model described above, have not rigorously excluded the possibility that GDP-bound RAS2 protein is capable of activating adenylyl cyclase. In addition, because crude yeast membrane extracts were used it was not certain that RAS2 protein interacts directly with adenylyl cyclase or through intermediate proteins. To understand the interaction between RAS and adenylyl cyclase in greater detail, we undertook to reconstitute the reaction with purified components. Adenylyl cyclase has proven difficult to purify by conventional methods, so we used the epitope addition method described below.
The epitope addition method of protein purification takes advantage of the powerful technique of monoclonal antibody affinity chromatography. The first step in our method was to construct a vector that encodes an epitope fusion protein. This fusion protein consists of a peptide epitope linked to the N-terminus of adenylyl cyclase. Next, a monoclonal antibody directed against the peptide epitope was used to purify the fusion protein. The choice for the epitope was based on the work of Green et al. (14) who demonstrated that small peptides corresponding to sequences from the hemagglutinin of the influenza virus (HA1) could be used to raise antibodies that reacted with the HAl protein itself. Niman et al. (23) subsequently developed several monoclonal antibodies to one of the peptide sequences, HAl (75-110), and Wilson et al. (43) demonstrated that a short 9-amino-acid sequence, YPYDVPDYA, contained the complete antigenic determinant of the immunizing 36-mer peptide. This peptide can be used to release the fusion protein from the monoclonal antibody.
MATERIALS AND METHODS
Vectors and strains. pT71TPKI, the TPKI expression vector, was a gift of M. Zoller (Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.). This vector contains the SalI-HindIII fragment of the cyclic AMP-dependent protein kinase TPK1 (37) cloned into the T7 promotor-based vector pT7 (16, 32) T ATG TAC CCA TAC GAT GTT CCA GAT TAC GCT AGC TTG GGT GGT CC  3'  AC ATG GGT ATG CTA CAA GGT CTA ATG CGATCG AAC CCA CCA GGA T into pT71TPKJ at the NdeI site which marks the start codon for TPKI. These oligonucleotides encode the HAl epitope. pPK5 was next constructed by first digesting pPK1 partially with NdeI and completely with EcoRV and isolating the fragment containing the HAl TPKJ fusion protein sequences. This fragment was ligated into the HindIll site of pAD1, a yeast expression plasmid containing the alcohol dehydrogenase I promoter (1). Both insert and vector were filled in with Klenow fragment before ligation. As a consequence, a BamHI-SaiI fragment of pPK5 contains the ADHI promotor and the epitope coding sequences. In parallel to these constructions, the oligonucleotide pair 5' TCG AGG ATC CGC GTC GAC GC 3' 3'
CC TAG GCG CAG CTG CGAGCT 5' was inserted into the Sall site of YRp7-CYRI (10), a plasmid containing both the CYR] gene and the TRPJ gene, to create pBM11. This addition created a BamHI site and a properly phased SalI site while destroying the endogenous Sall sites. pBM11 was digested with Sall and BamHI and ligated to the BamHI-SaiI fragment of pPK5, described above. The resulting plasmid, pEF-CYRI, was capable of suppressing the loss of adenylyl cyclase and also the loss of both RAS1 and RAS2. The auxotrophic marker TRPJ was therefore not required to maintain the plasmid in certain mutant strains of S. cerevisiae. For the studies described here, we used two strains interchangeably: JF27A[(MATa his3 leu2 ura3 trpl ade8 cyrl:: URA3(pEF-CYR1)] and JF36A [(MA Tot his3 leu2 ura3 trpl ade8 cani rasl::HIS3 ras2::URA3(pEF-CYRl )].
Immunological methods. Monoclonal antibody 12CA5, a subclone of H26D08 (mouse immunoglobulin G2b), was raised against influenza hemagglutinin peptide HAl (75-110) as described previously (23) . Cells expressing this antipeptide antibody were injected into mice to induce tumors, and the antibody was purified from ascites fluid. Western blots (immunoblots) were visualized with reagents from Bio-Rad Laboratories (Richmond, Calif.). In Fig. 2 , goat anti-mouse immunoglobulin G conjugated to horseradish peroxidase was used to identify the immunoreactive bands. In Fig. 3 , colloidal gold conjugated to goat anti-mouse immunoglobulin G was used (Bio-Rad). The peptide YPYDVPDYA was synthesized on an Applied Biosystems synthesizer by Dan Marshak (Cold Spring Harbor, N.Y.).
Preparation of RAS2 proteins and adenylyl cyclase assays. Adenylyl cyclase activity was measured and RAS2 proteins were prepared from Escherichia coli expression systems as described previously (3, 27) . Protein from RAS2Val-19, a mutant of RAS2, was used in some experiments to test activation of adenylyl cyclase. Protein determinations were by the method of Bradford (2) except when detergents were present. In these cases, the amido black method was used (28) . Each experiment described in this report was repeated at least twice. Similar results were obtained with two preparations of antibody and peptide and more than five preparations of yeast extracts.
Adenylyl cyclase solubilization. Solubilization of adenylyl cyclase from yeast membrane extracts was done by a modification of the method of Varimo and Londesborough (41) . First, yeast membranes were prepared as described previously (3, 38) from 1 to 5 liters of cells grown to a density of 2 x 107 cells per ml in YPD medium (1% yeast extract, 2% glucose, 2% peptone [Difco Laboratories, Detroit, Mich.]). Membranes were brought to a volume of 20 ml/liter of cells with buffer C (200 mM MES [2-(N-morpholino)ethanesulfonic acid, pH 6.2], 0.1 mM MgCl2, 0.1 mM EGTA, 1 mM P-mercaptoethanol, 1 mM phenylmethylsulfonyl fluoride) containing 1% Lubrol PX and 0.5 M NaCl. Then the membranes were centrifuged for 60 min at 35,000 rpm in a Beckman type 50 Ti rotor. The supernatant, which contained about 50% of the adenylyl cyclase activity, was stored at -80°C until needed.
Adenylyl cyclase purification. An extract from 5 liters of cells was prepared as described above to obtain fraction 1 (crude extract, 100 ml). This was passed through a 1-ml Sepharose CL-2B (Pharmacia, Uppsala, Sweden) column to remove proteins that nonspecifically bound Sepharose and was then loaded twice onto a monoclonal antibody 12CA5 column that had been prepared by cross-linking 2 mg of monoclonal antibody 12CA5 to 2 ml of CNBr-activated Sepharose 4B (Pharmacia) under conditions recommended by the manufacturer. The resin was prepared in a column that was surrounded by a water jacket and had been equilibrated with buffer C containing 1% Lubrol PX and 0.5 M NaCl at 4°C. After loading, the column was washed with 100 ml of buffer C containing 0.1% Lubrol PX and 0.5 M NaCl. To elute the bound protein, the column resin was mixed with 1 mg of the peptide YPYDVPDYA dissolved in 2.5 ml of the column buffer and prewarmed to 30°C. The jacket on the column was then flooded with water at 30°C and incubated for 15 min at 30°C. Care was taken during this step to mix the resin and the elution buffer to release air bubbles caused by the rapid warming of the resin. Fractions were collected, and the column was washed with 3 ml of column buffer at 30°C. The elution step was carried out twice and the peak fractions were pooled to obtain fraction 2 (immunoaffinity purified, 3.2 ml). More than 70% of the activity recovered was found in the first elution. Except for the relatively brief 30°C incubation described above, all steps were done at 0 to 4°C. After use, the column was regenerated by washing with 100 mM glycine (pH 2.9) followed by buffer C containing 1% Lubrol PX and 0.5 M NaCl. We have carried out this procedure more than five times with the same column.
A portion of fraction 2 (1.0 ml) was concentrated by centrifugation through a Centricon 10 microconcentrator (Amicon Corp., Danvers, Mass.) to a volume of 0.2 ml and then layered onto a 5-ml 10 to 35% glycerol gradient (buffer C containing 0.1% Lubrol PX and 0.5 M NaCl). The gradient was centrifuged for 13 h at 35,000 rpm in a Beckman SW50.1 rotor. After centrifugation, the tube was punctured and fractionated. Fractions were analyzed by silver-stained sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (20-,ul samples) and also assayed for adenylyl cyclase activity (5-,ul samples). Recovery of activity was about 50% for the concentration step and >50% for the gradient itself. A separate marker gradient was run in parallel and analyzed by SDS-polyacrylamide gel electrophoresis. Marker proteins were catalase, 11.3S; alcohol dehydrogenase, 7.6S; bovine serum albumin, 4.4S; ovalbumin, 3.5S; cytochrome c, 1.7S. Fig. 1 , along with the relevant sequences of the fusion protein and the sequence of the peptide. The peptide epitope is fused to the amino terminus of adenylyl cyclase. The amino acid sequence GGP was used to connect the peptide to the rest of the protein. This sequence was chosen as a linker because we thought it would cause the antigen to protrude from the protein. We did not test whether this linker is required for antigenic recognition. A total of 20 amino acids were added to adenylyl cyclase. To test the complementing activity of this expression system, we carried out plasmid exchange experiments. The adenylyl cyclase construction described above could suppress the loss of adenylyl cyclase and also the loss of RAS] and RAS2 (data not shown). This is consistent with previous observations that wild-type adenylyl cyclase expressed on a similar plasmid could also suppress these otherwise lethal mutations (10, 17, 19, 35) .
We first tested for the presence of the peptide epitope by subjecting extracts from the appropriate strains to Western blot analysis. When blots were probed with the antipeptide monoclonal antibody 12CA5, a band of 200 kilodaltons (kDa) was observed in cells containing pEF-CYRI (Fig. 2 ). This is close to the predicted molecular size of 220 kDa (17) . A band of this molecular size was not seen in extracts from cells that overexpressed adenylyl cyclase without the epitope fused to it. It should be noted that Western blots of some yeast extracts yielded additional bands reacting with the monoclonal antibody (Fig. 2, lane 1) . These bands were not present in all extracts and were even seen in extracts from cells that did Western blot analysis of antigen fusion proteins. In lanes 1 through 4 and 6, membrane extracts from S. cerevisiae harboring the indicated plasmids expressing the yeast adenylyl cyclase gene, CYRI, were subjected to SDS-polyacrylamide gel electrophoresis and then transferred to nitrocellulose paper. In lane 5, membranes from S. cerevisiae cells harboring pEF-CYRI were solubilized with 1% Lubrol PX and 0.5 M NaCl as described in Materials and Methods, immunoprecipitated with monoclonal antibody 12CA5, subjected to electrophoresis on an SDS-polyacrylamide gel, and transferred to nitrocellulose paper. Lane The final plasmid was constructed to express the peptide epitope fused to yeast adenylyl cyclase (CYRI), using the yeast alcohol dehydrogenase I (ADH) promoter. The antibody-binding sequence YPYDVPDYASL is from the influenza hemagglutinin HAl, but the antibody also recognizes the shorter sequence YPYDVPDYA. S. cerevisiae sequences are shown by heavy lines, and E. coli sequences are shown by light lines. The oligonucleotide encoding the epitope is shown by an open box. Abbreviations for restriction sites are as follows: B, BamHI; H/N, HindIII-NdeI junction; S, Sall; C, ClaI. AMPR, Ampicillin resistance. not contain pEF-CYRI. Thus, they appear to be caused by cross-reactivity of the antibody with other yeast proteins.
Immunoprecipitation and purification of adenylyl cyclase. We continued our studies with the epitope-fused adenylyl cyclase to see whether it could be purified by monoclonal antibody affinity chromatography. First, it was necessary to determine whether the adenylyl cyclase could interact with the monoclonal antibody in a soluble system. To do this, we solubilized the normally membrane-associated adenylyl cyclase with Lubrol PX and NaCl, immunoprecipitated with antibody, and then subjected the samples to Western blot analysis as described in Materials and Methods. In Fig. 2 , lanes 5 and 6, the solubilized and immunoprecipitated fraction is compared with a membrane fraction. Both fractions yielded the expected 200-kDa band, indicating that soluble adenylyl cyclase could react with the antibody. Enzymatic assays of adenylyl cyclase immunoprecipitation experiments are shown in Table 1 . About 50% of the epitope-fused adenylyl cyclase activity was depleted from a solubilized extract by the antibody 12CA5. No activity was depleted when immunoprecipitations were done in the presence of a large excess of the peptide YPYDVPDYA, which is known to bind to the antibody, or from extracts that overexpress wild-type adenylyl cyclase. The activity not depleted from the extract probably represents proteolytic fragments of adenylyl cyclase that have lost the epitope but are still catalytically active. To determine whether the immunoprecipitated adenylyl cyclase was still active, we carried out enzymatic assays on the agarose beads used to deplete the extracts (Table 1 ). More than 50% of the activity depleted by the antibody could be found in the immobilized fraction. a Membranes from yeast strains expressing epitope-fused adenylyl cyclase (experiment 1) or wild-type adenylyl cyclase (experiment 2) were treated with buffer C containing 1% Lubrol PX and 0.5 M NaCI to solubilize adenylyl cyclase. Where indicated, 200 iL1 of extract was then incubated with 30 jig of monoclonal antibody 12CA5 or 50 pig of peptide YDYDVPDYA for 5 h at 4°C followed by a second incubation with 50 pul of 50% protein A-agarose for 3 h at 4°C. The pellets were washed twice with solubilization buffer and brought to a final volume of 130 pul. Adenylyl cyclase assays were done with 50 ,ul of supernatant or 10 ,ul of pellet. The data are expressed as if the entire sample has been assayed.
Encouraged by the observations that the solubilized adenylyl cyclase reacted with the monoclonal antibody and was still active when immobilized by the antibody, we sought to develop an immunoaffinity purification step. We began by testing on an analytical scale a number of commonly used methods for immunoaffinity chromatography elutions. However, urea concentrations of more than 2.0 M or glycine buffers lower than pH 3.5 inactivated the adenylyl cyclase activity in these experiments. The peptide YPYDVPDYA could elute the antibody-bound adenylyl cyclase activity, but only when incubated at the relatively high temperature of 30°C (data not shown). To carry out the purification, we cross-linked the antibody to a Sepharose matrix and then subjected solubilized yeast extracts to a column chromatography procedure. Elution from the column was done by competing away the immobilized enzyme with a large excess of the peptide YPYDVPDYA incubated at 30°C for 15 min. Table 2 shows the results of a purification procedure. Overall purification was about 700-fold. Recovery was about 20% of the starting activity or about 40% of the bound activity. Most of the activity lost was probably due to heat inactivation by the 30°C temperature used for elution.
We further characterized the immunopurified fraction by subjecting it to SDS-polyacrylamide gel electrophoresis. When visualized with silver stain, major bands of 200, 150, and 70 kDa were observed along with several minor bands (Fig. 3A ). This pattern of bands was the same in preparations from rasi ras2 CYRJ(pEF-CYRI) cells (JF36A) as well as preparations from RAS] RAS2 cyrl(pEF-CYRI) cells (JF27A). Neither of these strains yielded bands in the size range of RAS] or RAS2 (data not shown). To determine which of these bands corresponded to the adenylyl cyclase fusion protein, we electrophoresed samples through an SDSpolyacrylamide gel and then transferred the proteins to nitrocellulose paper. We stained a portion of the blot for total protein using colloidal gold (Fig. 3B ) and subjected another portion of the blot to Western blot analysis using the monoclonal antibody 12CA5 (Fig. 3B ). In the portion stained for total protein, we detected a pattern of bands nearly " Extracts from a yeast strain harboring pEF-CYRI were chromatographed on a monoclonal antibody column as described in Materials and Methods. The recovery of activity actually bound to the column was 45%. Assays were done with Mn2+ as the divalent cation. The protein concentration of fraction 2 was too low to measure. identical to that in the silver-stained gel, while in the portion probed with monoclonal antibody 12CA5, we detected only a single band of about 200 kDA. Thus, the 200-kDA band seen after visualizing total protein is probably the adenylyl cyclase fusion protein. The exact assignment of the 200-kDA band was not possible because in the total protein blot a doublet was observed in this region, while in the Western blot only a single band was observed. To determine whether the 200-kDa protein binds to either of the other two major proteins in our preparation, we subjected a portion of the preparation to glycerol gradient sedimentation, fractionated the gradient, and then assayed the various fractions in the gradient (Fig. 4) . The adenylyl cyclase activity sedimented with an S value of about 15S which is close to the value of 12.5S previously reported for solubilized adenylyl cyclase (15) . A silver-stained SDS-polyacrylamide gel indicated that the 200-and 70-kDa bands, but not the 150-kDa band, cosedimented with the peak fractions of activity. We are presently investigating what relationship, if any, the 70-kDa protein has to adenylyl cyclase. Heideman et al (15) FIG. 4. Glycerol gradient sedimentation of immunopurified adenylyl cyclase. Gradients were run as described in Materials and Methods. The gradient fractions were analyzed on silver-stained SDS-polyacrylamide gels (above) and also by adenylyl cyclase assays (below). Inset, S value determination by comparison with standards. Arrow indicates peak of adenylyl cyclase activity. Symbols: 0, Mn2"; 0, Mg2"; , Mg2" plus 12 ,ug of RAS2val-19 protein.
cAMP, Cyclic AMP. clase to be 594 kDa, and Varino and Londesborough have determined the molecular size of adenylyl cyclase to be 450 kDa (41) . Thus, adenylyl cyclase appears to consist of a multisubunit complex containing the 200-kDa CYR] gene product and an unidentified 70-kDa polypeptide. Activation of adenylyl cyclase by RAS2 protein and guanine nucleotides. Purified yeast RAS2 and RAS2VaIl9 proteins are known to activate wild-type adenylyl cyclase in crude membrane fractions. Optimum activation requires RAS2 or RAS2VaI-l9 protein bound to GTP and takes place when Mg2+ is used as the divalent cation (3, 9, 10). When Mn2+ is used, as in the experiments described above, RAS2 protein is not needed for activation (3, 5) . To test the RAS2 protein responsiveness of adenylyl cyclase, we used a mutant form of RAS2 protein, RAS2vVa-1l9 protein, purified from an E. coli expression system. This protein is deficient in its GTPase activity. We found it fully capable of stimulating adenylyl cyclase without the addition of exogenous GTP, presumably because it is predominantly in its GTP-bound state. RAS2va-19 protein activation of various epitope-fused adenylyl cyclase fractions is shown in Table 3 . The crude membrane preparation, solubilized membrane preparation, immobilized fraction, and purified protein were all greatly stimulated by RAS2Val-9 protein when Mg" was present as the divalent cation. The peaks of Mn2+-dependent activity and RAS2Val-19-responsive activity also cosedimented through a glycerol gradient (Fig. 4) . When the ratio of Mn/Mg2+ RAS2Val-19 protein activity was compared, we found that about half of the RAS2 protein activation was lost during the solubilization procedure (Table 3) . This is probably caused by the addition of NaCl, which is required, along with Lubrol PX, to solubilize adenylyl cyclase. Other experiments have shown that NaCl, but not Lubrol PX, inhibits adenylyl cyclase in the RAS2 protein activation assay, but not in the Mn2+ assay (data not shown). Thus, the purified adenylyl cyclase complex is fully activated by RAS2Val-l9 protein.
We also tested the ability of wild-type RAS2 protein to activate the purified adenylyl cyclase. We previously found that GDP-bound wild-type RAS2 protein was capable of partially activating adenylyl cyclase in crude membrane preparations. However, RAS2 protein bound to the stable analog of GDP, GDP-PS, was inactive (3, 10). To determine whether the partial activation of GDP-bound RAS2 protein was still observed with highly purified adenylyl cyclase, we tested various guanine nucleotides in RAS2 protein activation assays (Fig. 5 ). RAS2 protein activated adenylyl cyclase when bound to GTP, but not when bound to GDP or GDP-PS. RAS2 protein incubated without any exogenously added nucleotide was not capable of activating adenylyl cyclase, suggesting that it is not bound to GTP when we purify it from E. coli expression systems. Taken together, these results indicate that RAS2 protein activates adenylyl cyclase when bound to GTP, but not GDP, and that in crude membranes some unknown mechanisms converts GDPbound RAS2 protein to GTP-bound RAS2 protein.
DISCUSSION
We have been studying the RAS protein interactions with the adenylyl cyclase of S. cerevisiae as a model for mammalian ras effector interactions. Uno et al. (40) have reported the expression of a fragment of adenylyl cyclase in E. coli which they claim is stimulated by RAS proteins, sug- 12 ,ug of RAS2Val19 protein bound to GTP. Experiment 1 compares a membrane extract, a soluble fraction, and a solubilized membrane extract that was immobilized to agarose beads with monoclonal antibody 12CA5. All three samples were from the same crude cell lysate. Experiment 2 compares a solubilized membrane fraction and a purified adenylyl cyclase fraction prepared frorh the same original crude cell lysate. The amount of each extract tested was chosen to give roughly comparable levels of activity in the presence of Mn2'. VOL. 8, 1988 on gesting a direct interaction between R adenylyl cyclase. We have been unable t results and are not able to express a adenylyl cyclase in E. coli (17) . Indeed, adenylyl cyclase which they express in appear to be RAS responsive when we ex (unpublished data). We have utilized S. c sion systems to study this problem. In describe the purification of adenylyl cyclas siae using an immunoaffinity procedure. A umn passage, there is ehrichment of at second procedure, glycerol gradient se creases the purification severalfold and 4 purified enzyme is a multisubunit comple haps two copies of the 200-kDa CYRI g some numnber of an unidentified 70-kDa pro enzyme was fully activated by RAS2 proti purified adenylyl cyclase was still activat tein, it is still not certain whether RAS2 directly with adenylyl cyclase, through th4 or by acting on the complex itself. Th transduction activation of cyclic GMP p sets a precedent for complex interaction thought to act by releasing inhibition of subunit of the phosphodiesterase compl presently trying to determine whether the required for RAS2 protein stimulation of has other functions related to adenylyl cyc an artifact of purification. It is widely believed that RAS proteins signal transduction pathways and are cap' their effectors when bound to GTP but nc GDP. The guanine nucleotide content i regulated by RAS itself through its GI possibly by other proteins (4, 26, 39) . The cyclase assay enabled us to test the gu response of RAS protein directly. Prev measured adenylyl cyclase activity in cru tracts, we found that GDP-bound RAS2 protein was capable > of activating adenylyl cyclase (3, 10). We found here that the purified adenylyl cyclase is not activated by GDP-bound RAS2 protein. Thus, it appears that GDP-bound RAS2 protein is not capable of activating adenylyl cyclase and that some unknown mechanism(s) exists in the crude membranes for creating GTP-bound RAS2 protein from GDP-bound RAS2 protein. One enzyme responsible for the activation by GDP-bound RAS2 protein in crude extracts is likely to be a dinucleotide kinase because GDP-PS-bound RAS2 protein is not active in crude extracts, and unlike GDP, GDP-PS is incapable of being phosphorlyated to GTP. Similar ambiguities observed with vertebrate adenylyl cyclase have been linked to a dinucleotide kinase activity (20) .
We described a broadly applicable genetic method for ,^fusing epitopes to proteins and then purifying the fusion 10 12 14 proteins by using the appropriate monoclonal antibody affinity column. The system can theoretically be used with any clase by wild-type cloned gene. Furthermore, because the peptide epitope is so ides. The indicated small, only 9 amino acids in length, the resultant epitope bated with 5 pd of fusion protein is less likely to differ significantly in function the divalent cation from the wild-type protein than larger fusion proteins are.
ation with adenylyl For the studies presented here, we fused the epitope to the re preincubated for amino terminus of adenylyl cyclase because previous studies leotide (LI), 50 p.M indicated that these constructions would be unlikely to (A) . cAMP, Cyclic interfere with enzymatic activity. It obviously is easier to design vectors which contain both the promoter and the epitope in one piece, enabling the gene of choice to be 'AS protein and inserted as a cassette. However, the epitope would probably o duplicate these be recognized if fused to the carboxyl terminus (see, for RAS-responsive example reference 22) or even within the polypeptide backthe fragment of bone. The fusion proteins can be purified by immunoaffinity E. coli does not chromatography. Antibody-antigen interactions are fre-,press it in yeasts quently too tight to reverse easily. Many procedures used to erevisiae expres-elute material from antibody affinity columns exploit exthis report, we treme pHs or chaotropic agents and subsequently inactivate se from S. cerevi-the enzyme being purified. We found that adenylyl cyclase kfter a single colwas inactivated by a number of these procedures. The least 700-fold. A method finally chosen, incubation with the synthetic peptide dimentation, in-epitope, was relatively gentle and should be useful with suggests that the other proteins as well. Should it be necessary to separate the x containing per-synthetic peptide from the purified protein, one could use a yene product and number of procedures designed to exploit their size differitein. The 
